Eli Lilly and Company
For nearly 150 years, we’ve made significant and game-changing progress on our mission to make life better for people around the world. We’ve remained headquartered in Indianapolis, Indiana, since our founding on May 10, 1876, but our employees now work in countries around the world.
And thanks to the dedication of our diverse global team, we’ve been able to answer the call for new medicines to help solve some of the world’s most significant health challenges
When you’re on a mission to do what’s never been done before, you seek people willing to challenge the status quo of medicine. Those willing to relentlessly pursue what’s next, all in the name of health above all. #WeAreLilly
We are Lilly
Why do our employees love coming to work each and every day? Here’s what they have to say.
47,000 global employees coming together from diverse backgrounds to create medicines that make life better for people around the world. Get to know Team Lilly through our Powered by Purpose series.
NEWS
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 26, 2020.
Diabetes and obesity remain a problem, even during a pandemic. Eli Lilly is continuing to develop the 13 diabetes drugs it has in Phase I through Phase III trials, with data from various trials planned for release throughout the coming year.
Eli Lilly is moving quickly to get a newly-approved precision oncology treatment, Retevmo, for certain lung and thyroid cancers into the hands of patients.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 4, 2020.
With the trillions of antibodies the human body can make, finding the antibody with the right combination of potency against a target and ease of manufacturing is, at best, an arduous, time-intensive endeavor for drug developers. AbCellera Biologics has developed a way to dramatically speed that process.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 24, 2020.
There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.
Many people have lost their jobs and, as a result, their insurance. That can be daunting enough, but for those who need life-saving drugs such as insulin, the situation is magnified.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 8, 2020.
JOBS
IN THE PRESS